Progeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with rapamycin and dimethylsulfoxide
نویسندگان
چکیده
منابع مشابه
Progeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with rapamycin and dimethylsulfoxide
Patients with progeroid syndromes such as mandibuloacral dysplasia, type B (MADB) and restrictive dermopathy (RD) harbor mutations in zinc metalloproteinase (ZMPSTE24), an enzyme essential for posttranslational proteolysis of prelamin A to form mature lamin A. Dermal fibroblasts from these patients show increased nuclear dysmorphology and reduced proliferation; however, the efficacy of various ...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin
Background: Management of multiple sclerosis (MS) is based on the usage of immunosuppressive and immune-modulating medications. Cytokines play an important role in the pathogenesis of MS. Objective: To evaluate the effects of rapamycin on the concentrations of Th1/Th2/Th17 serum cytokines in patients with MS. Methods: Six patients with relapsing remitting MS as a case group and 6 healthy indivi...
متن کاملWhen marketing and science intersect: do patients with MS benefit?
MS entered the treatment era a scant 9 years ago with US Food and Drug Administration (FDA) approval of interferon -1b. Since then, two interferon -1a preparations, an amino acid polymer, glatiramer acetate; and a chemotherapeutic agent, mitoxantrone, have received regulatory approval in the United States and many other countries for various forms of relapsing MS. Approval is based on modest bu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Case Studies
سال: 2016
ISSN: 2373-2865,2373-2873
DOI: 10.1101/mcs.a001339